S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
Log in
NASDAQ:RCKT

Rocket Pharmaceuticals Insider Trades

$52.93
-2.01 (-3.66 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$52.64
Now: $52.93
$55.44
50-Day Range
$51.85
MA: $56.87
$65.91
52-Week Range
$9.01
Now: $52.93
$67.48
Volume389,205 shs
Average Volume473,648 shs
Market Capitalization$2.92 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.05

Insider Trades

Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Buying and Selling Activity

Insider Ownership Percentage: 41.40%
Insider Buying (Last 12 Months): $13,881,820.00
Insider Selling (Last 12 Months): $950,683.92

Insider Buying and Selling by Quarter


Rocket Pharmaceuticals (NASDAQ RCKT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/28/2020Kinnari PatelCOOSell16,761$56.72$950,683.92100,404  
12/10/2020Rtw Investments, LpDirectorBuy247,720$56.00$13,872,320.00  
3/18/2020Kinnari PatelCOOBuy1,000$9.50$9,500.00111,738  
12/10/2019Rtw Investments, LpDirectorBuy225,000$22.25$5,006,250.00  
4/16/2019Rtw Investments, LpDirectorBuy550,005$17.50$9,625,087.50  
3/5/2019Gaurav ShahInsiderSell74,900$17.17$1,286,033.00  
12/13/2018David P SouthwellDirectorSell38,768$15.19$588,885.92  
12/7/2018David P SouthwellDirectorSell57,732$15.13$873,485.16  
12/6/2018Kinnari PatelCOOBuy5,675$14.98$85,011.50  
8/1/2018Naveen YalamanchiDirectorSell637$22.00$14,014.00  
1/6/2017David P. SouthwellInsiderBuy60,000$1.75$105,000.00  
5/13/2016J Martin CarrollDirectorBuy10,000$9.03$90,300.0010,000  
2/23/2015Argeris N KarabelasDirectorBuy603,832$6.00$3,622,992.00  
2/23/2015Park Bioventures Lp DevonMajor ShareholderBuy814,166$6.00$4,884,996.00  
(Data available from 1/1/2013 forward)
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.